, Richmond, B.C., Canada), which uses the principle of immunofiltration of HIV-1 [glycoprotein 41 (gp41)] and HIV-2 (gp36) recombinant proteins. Because of the wide variety of inclusion criteria, the study was intended to include at least 500 patients over a 6-month period, starting in August 2010. By the end of this time-frame, however, fewer than 50 patients had been included in the study. We organized several meetings and coaching sessions with the different

teams taking part in the study and decided to ask the same doctors to record information about a larger number of consultations, the purpose of which was to survey how many HIV tests had actually been offered. From August Bleomycin ic50 2010 to August 2011, 224 patients were included in the study, of whom 51.0% were male and 48.0% female (1% unknown); 45.0% were Caucasian, 46.5% African and 8.5% of other ethnicity; 48.2% were of Belgian nationality, 24.0% of a sub-Saharan African nationality and 12% of a European nationality other than Belgian. In terms of fulfilling the inclusion criteria, 32% belonged to a high-prevalence group, 29% had an indicator condition, and 9% had returned from

an endemic country. A standard test was offered to 217 patients (97%). Twelve patients (6%) refused the standard test because they were not covered by national health insurance or fear of losing anonymity, and 203 standard tests were performed. The INSTI HIV-2/HIV-2 test was offered to 217 patients (97%). Thirteen patients (6%) refused rapid testing because it was too stressful or because Everolimus cost they were not ready to receive a result immediately, and 197 tests were performed. Two reactive rapid tests were confirmed by Western blot; one rapid test proved indeterminate in the case of an HIV-negative person. The characteristics of

the two individuals with a confirmed reactive HIV test were as follows. The first person was a 45-year-old black man who was born in Mauritania, and left his home country and arrived in Belgium in 1999. He Phosphoprotein phosphatase travelled to Mauritania in April 2010; at the time of inclusion and testing in January 2011, he had Belgian citizenship, presented with dermatitis and had never been tested for HIV, HBV or HCV; his CD4 count was 171 cells/μL, defining him as a very late presenter. The second person was a 40-year-old black man from the Democratic Republic of Congo. The date of his arrival in Belgium was unknown, and he had not recently travelled to an HIV-endemic country. Before being tested, he said he had never been tested before for HIV, HBV or HCV, but when confronted with a positive rapid test result, he said he knew he was HIV positive. The seroprevalence according to the demographic characteristics of the patient populations of the different centres varied from 0 − 0.